Skip to main content

Advertisement

SpringerLink
Log in

Novel antineoplastic agents

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eckhardt SG, Rizzo J, Sweeney KR, et al.: Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumor. J Clin Oncol 1999, 17:1095–1104.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics Program, Cleveland Clinic Cancer Center, S33, 9500 Euclid Avenue, 441195, Cleveland, OH, USA

    Ronald M. Bukowski MD

Authors
  1. Ronald M. Bukowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R.M. Novel antineoplastic agents. Curr Oncol Rep 2, 9–10 (2000). https://doi.org/10.1007/s11912-000-0004-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-000-0004-1

Keywords

Search

Navigation